The U.S. Food and Drug Administration (FDA) this week announced its approval of Merck's Zepatier -- a once-daily coformulation containing the hepatitis C virus (HCV) protease inhibitor grazoprevir and NS5A inhibitor elbasvir -- for the treatment of HCV genotypes 1 and 4. In several Phase 3 studies grazoprevir/elbasvir taken for 12 weeks demonstrated cure rates exceeding 90% for various groups including people with liver cirrhosis, HIV/HCV coinfected patients, and people who inject drugs.
Antiretroviral treatment for everyone living with HIV, expansion of pre-exposure prophylaxis (better known as PrEP) for HIV prevention, and access to interferon-free therapies for hepatitis C topped the HIV and viral hepatitis headlines this year and will continue to be major issues going into 2016. Here's a look back at some of our biggest news from 2015.
HIVandHepatitis.com coverage of the 2015 National HIV Prevention Coference, (NHPC 2015), December 6-9 in Atlanta.
Conference highlights include HIV pre-exposure prophylaxis (PrEP), antiretroviral treatment as prevention, syringe exchange, and addressing disparities in HIV incidence and outcomes.
HIVandHepatitis.com coverage of the 2015 American Association for the Study of Liver Diseases (AASLD) Liver Meeting in San Francisco, November 13-17, 2015.
Conference highlights include interferon-free therapy for hepatitis C, treatment for difficult-to-treat populations including people with HCV genotype 3 and liver cirrhosis, hepatitis B prevention and treatment, and management of advanced liver disease.